This amalgamation may offer a multifaceted approach, leveraging both genetic and protein-level information, providing a more nuanced understanding of tumor dynamics and offering refined risk stratification strategies for personalized patient care in hepatoblastoma and other cancers where AFP and ctDNA play pivotal roles as biomarkers. The gene discussed is AFP; the disease is hepatoblastoma.